ETNB Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to 89bio's net margin of 8.48%. 89bio's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

89bio has a consensus price target of --, signalling upside risk potential of 279.41%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.68%. Given that 89bio has higher upside potential than Eli Lilly and, analysts believe 89bio is more attractive than Eli Lilly and.

89bio has a beta of 1.014, which suggesting that the stock is 1.371% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. 89bio pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

89bio quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. 89bio's net income of -$149.1M is lower than Eli Lilly and's net income of $970.3M. Notably, 89bio's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -172.04%. 89bio's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -89.04%.

89bio has a consensus price target of --, signalling upside risk potential of 279.41%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 19.55%. Given that 89bio has higher upside potential than Madrigal Pharmaceuticals, analysts believe 89bio is more attractive than Madrigal Pharmaceuticals.

89bio has a beta of 1.014, which suggesting that the stock is 1.371% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. 89bio's net income of -$149.1M is lower than Madrigal Pharmaceuticals's net income of -$107M. Notably, 89bio's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -49.65%. 89bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

89bio has a consensus price target of --, signalling upside risk potential of 279.41%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than 89bio, analysts believe NovaBay Pharmaceuticals is more attractive than 89bio.

89bio has a beta of 1.014, which suggesting that the stock is 1.371% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 89bio's net income of -$149.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, 89bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to 89bio's net margin of --. 89bio's return on equity of -- beat Viking Therapeutics's return on equity of --.

89bio has a consensus price target of --, signalling upside risk potential of 279.41%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.74%. Given that 89bio has higher upside potential than Viking Therapeutics, analysts believe 89bio is more attractive than Viking Therapeutics.

89bio has a beta of 1.014, which suggesting that the stock is 1.371% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. 89bio's net income of -$149.1M is lower than Viking Therapeutics's net income of -$24.9M. Notably, 89bio's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.